All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
The FDA grants annamycin Orphan Drug Designation for the treatment of AML
Bookmark this article
On 22nd March 2017, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to annamycin for the treatment of patients with Acute Myeloid Leukemia (AML).1
Current anthracyclines such as doxorubicin used in standard chemotherapy for AML patients are associated with risk of cardiotoxity as well as drug resistance.2 Annamycin (liposomal annamycin) is a liposome-encapsulated form of the anthracycline doxorubicin, with antineoplastic activity. Annamycin evades cellular Multidrug-Resistance (MDR) mechanisms and eliminates cardiotoxicity.1
Moleculin Biotech, the drug manufacturer, is working toward an Investigative New Drug application for a phase I/II trial with annamycin for second line treatment in patients with Relapsed or Refractory AML.1
- BioSpace: Moleculin Biotech (MBRX) Receives Orphan Drug Designation For Annamycin For The Treatment Of Acute Myeloid Leukemia. 2017 Mar 22. http://www.biospace.com/news_story.aspx?StoryID=450411&full=1 [Accessed 2017 Mar 23].
- Jungsuwadee P. Doxorubicin-induced cardiomyopathy: an update beyondoxidative stress and myocardial cell death. Cardiovasc Regen Med. 2016; 3: e1127. DOI: 10.14800/crm.1127.
More about...
Your opinion matters
15 votes - 80 days left ...
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox